NBE-Therapeutics
NBE-Therapeutics develops antibody-drug conjugates (ADCs) for the treatment of solid tumors. The company utilizes a proprietary platform involving PNU anthracycline payloads and site-specific conjugation to create targeted oncology medicines. These therapies are designed to induce a long-lasting immune-oncology effect to reduce or eradicate tumors in cancer patients.
Biotechnology
Oncology
Healthcare
Funding summary
- Total raised
- €61.5M
- Funding rounds
- 4
Investors in NBE-Therapeutics
Investors on record for NBE-Therapeutics. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like NBE-Therapeutics?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors